Top 5 Atrial Fibrillation Companies

Atrial fibrillation (AFib) is one of the most common cardiac arrhythmias and represents a significant clinical burden owing to its association with stroke, heart failure and other cardiovascular complications. Globally, atrial fibrillation affects more than 59 million individuals, creating substantial demand for effective approaches that can restore or maintain normal cardiac rhythm and reduce AFib-associated complications.

Over the years, the treatment landscape for atrial fibrillation has evolved considerably, moving beyond conventional pharmacological rhythm and rate control approaches toward minimally invasive and device-based interventions. Catheter ablation has emerged as an important treatment modality, while technologies such as three-dimensional cardiac mapping, contact-force sensing and left atrial appendage management have further improved procedural capabilities. More recently, pulsed field ablation (PFA) has gained significant prominence as companies seek to provide rapid, tissue-selective alternatives to conventional thermal ablation.

Consequently, several established cardiovascular device manufacturers are expanding their electrophysiology portfolios through new ablation catheters, integrated mapping platforms, advanced energy-delivery systems and left atrial appendage closure technologies. Notably, major companies are increasingly developing integrated platforms that combine mapping, visualization and ablation within streamlined workflows, while simultaneously generating clinical evidence across paroxysmal and persistent forms of atrial fibrillation.

As innovation in the atrial fibrillation market continues, healthcare providers are likely to gain access to an increasingly diversified range of treatment options tailored to disease stage, patient anatomy and underlying clinical risk. This evolving treatment paradigm is creating significant opportunities for atrial fibrillation companies to expand their product portfolios and strengthen their presence across the global cardiac electrophysiology market.

Roots Analysis has conducted an exhaustive study on Atrial Fibrillation Market featuring the current market landscape and future opportunities for companies engaged in healthcare, over the span of next 9 years.

Top Five Atrial Fibrillation Companies

1. Abbott
2. AtriCure
3. Boston Scientific
4. Johnson & Johnson
5. Medtronic

The figure below highlights the top five atrial fibrillation companies:

Interested in exploring all ~120 players offering atrial fibrillation devices, along with their recent initiatives?

Discover Below the Details on Top 5 Atrial Fibrillation Companies

Let us dive deep into the details of the top atrial fibrillation companies. It is essential to note that the selection of top players can differ substantially according to the defined criteria.

1. Abbott

Company Overview

Abbott is a global healthcare company with an established presence in cardiovascular care and cardiac electrophysiology. Within the atrial fibrillation domain, the company offers technologies spanning cardiac mapping, radiofrequency ablation and pulsed field ablation. Its EnSite X EP System supports visualization and localization of electrophysiology catheters during cardiac procedures, while its TactiFlex family of ablation catheters incorporates contact-force sensing to support controlled lesion delivery during AFib ablation procedures.

More recently, Abbott has strengthened its PFA portfolio through the Volt PFA System and TactiFlex Duo Ablation Catheter, Sensor Enabled. Volt is indicated in the US for symptomatic, recurrent, drug-refractory paroxysmal or persistent atrial fibrillation and is compatible with the EnSite X EP System. Further, the TactiFlex Duo platform has been designed to provide physicians with the flexibility to deliver both radiofrequency and pulsed field energy.

List of Atrial Fibrillation Devices Offered Based on Product Name, Device Type, Ablation Energy Source, and Integrated Technologies

The section provides information on various atrial fibrillation solutions being offered by Abbott, along with details on the product name, device type, ablation energy source, and integrated technologies.

• Product Name: TactiFlex™ Ablation Catheter, Sensor Enabled™, Volt™ Pulsed Field Ablation System, Amplatzer™ Amulet™ Left Atrial Appendage Occluder, and TactiCath™ Contact Force Ablation Catheter
• Device Type: Ablation Systems, Catheters, and LAA Closure Devices
• Ablation Energy Source: Pulse Field, Radiofrequency, and Cryoablation
• Integrated Technologies: Contact Force Sensing

Recent Developments

In January 2026, Abbott highlighted the US FDA approval of its Volt PFA System, representing the company's first PFA offering for patients in the US. During the same period, the company also reported CE Mark authorization for the TactiFlex Duo Ablation Catheter, designed to deliver both radiofrequency and PFA energy for atrial fibrillation treatment. Subsequently, Abbott reported that the US launch of Volt and expanding international rollout of Volt and TactiFlex Duo contributed to growth within its electrophysiology business during the second quarter of 2026.

To know more about the recent initiatives of Abbott and other atrial fibrillation companies, access full report.

2. AtriCure

Company Overview

AtriCure is a medical technology company focused extensively on surgical treatments for atrial fibrillation, left atrial appendage management and related cardiac conditions. Unlike companies primarily focused on catheter-based electrophysiology, AtriCure has established a differentiated position through surgical and hybrid AFib treatment solutions. Its portfolio includes the Isolator Synergy Ablation System, EnCompass Clamp, EPi-Sense System and AtriClip Left Atrial Appendage Exclusion System.

The company's Hybrid AF Therapy combines epicardial and endocardial approaches to address long-standing persistent atrial fibrillation. In addition, AtriCure's AtriClip portfolio is designed for left atrial appendage exclusion, addressing an important source of thromboembolic complications associated with atrial fibrillation. The company states that its Isolator Synergy Ablation System was the first medical device to receive FDA approval for persistent and long-standing persistent AFib.

List of Atrial Fibrillation Devices Offered Based on Product Name, Device Type, Ablation Energy Source, and Integrated Technologies

The section provides information on various atrial fibrillation solutions being offered by AtriCure, along with details on the product name, device type, ablation energy source, and integrated technologies.

• Product Name: Isolator® Synergy™ Ablation System, EPi-Sense System, EPi-Sense ST System, AtriClip FLEX-Mini Device, AtriClip FLEX•V Device, AtriClip FLEX Device, AtriClip PRO-Mini Device, AtriClip PRO•V Device, AtriClip PRO2 Device, AtriClip PRO Device
• Device Type: Ablation Systems and LAA Closure Devices
• Ablation Energy Source: Radiofrequency

Recent Developments

In December 2025, AtriCure announced the first-in-human use of a novel dual-energy surgical ablation platform combining pulsed field ablation with advanced radiofrequency ablation through its EnCompass clamp. In the first two treated patients, the company reported that the total ablation time required to create a box lesion isolating the pulmonary veins and posterior left atrial wall was less than 60 seconds. The advanced RFA and PFA technologies remain investigational and were not approved for commercial use at the time of the announcement.

To know more about the recent initiatives of AtriCure and other atrial fibrillation companies, access full report.

3. Boston Scientific

Company Overview

Boston Scientific is a prominent medical device company with an extensive portfolio for cardiac electrophysiology and structural heart interventions. The company's presence in atrial fibrillation management is anchored by its FARAPULSE Pulsed Field Ablation Platform, which provides a nonthermal approach to cardiac ablation. Its portfolio includes FARAWAVE and FARAWAVE NAV PFA catheters as well as mapping and navigation technologies intended to support electrophysiology procedures.

In addition to rhythm management, Boston Scientific participates in the prevention of AFib-associated thromboembolic complications through its WATCHMAN left atrial appendage closure portfolio. This combination of ablation and LAA closure technologies positions the company across multiple stages of AFib management and enables it to address both abnormal cardiac rhythm and associated stroke risk in appropriate patients.

List of Atrial Fibrillation Devices Offered Based on Product Name, Device Type, Ablation Energy Source, and Integrated Technologies

The section provides information on various atrial fibrillation solutions being offered by Boston Scientific, along with details on the product name, device type, ablation energy source, and integrated technologies.

• Product Name: FARAPULSE™ Pulsed Field Ablation System, FARAWAVE™ Pulsed Field Ablation Catheter, FARAPOINT™ Pulsed Field Ablation (PFA) Catheter, WATCHMAN FLX, WATCHMAN FLX Pro, and POLARx™ Cryoablation System
• Device Type: Ablation Systems, Catheters, and LAA Closure Devices
• Ablation Energy Source: Pulse Field and Cryoablation
• Integrated Technologies: Ballon-based

Recent Developments

In April 2026, Boston Scientific presented results from the AVANT GUARD clinical trial, which evaluated FARAPULSE PFA as first-line therapy versus antiarrhythmic drugs in previously untreated patients with persistent atrial fibrillation. The trial demonstrated superiority of PFA over antiarrhythmic drug therapy for its primary effectiveness endpoint. The company also presented early clinical evidence for its investigational FARAFLEX map-and-ablate PFA catheter and real-world data evaluating combined FARAWAVE PFA and WATCHMAN FLX Pro procedures.

To know more about the recent initiatives of Boston Scientific and other atrial fibrillation companies, access full report.

4. Johnson & Johnson

Company Overview

Johnson & Johnson, through its cardiovascular and electrophysiology business, has developed an extensive range of technologies for the diagnosis and treatment of cardiac arrhythmias. Its AFib portfolio combines three-dimensional electroanatomical mapping, navigation, intracardiac visualization and catheter ablation, enabling physicians to plan and perform electrophysiology procedures using an integrated technology ecosystem.

A key component of the company's recent atrial fibrillation strategy is the VARIPULSE Platform, which combines a variable-loop PFA catheter, TRUPULSE Generator and CARTO 3 Mapping System. The platform was designed to integrate PFA treatment with electroanatomical mapping, thereby providing real-time visualization and supporting a streamlined ablation workflow.

List of Atrial Fibrillation Devices Offered Based on Product Name, Device Type, Ablation Energy Source, and Integrated Technologies

The section provides information on various atrial fibrillation solutions being offered by Johnson & Johnson, along with details on the product name, device type, ablation energy source, and integrated technologies.

• Product Name: VARIPULSE™, THERMOCOOL SMARTTOUCH® Catheter, QDOT MICRO™ Catheter, Dual Energy THERMOCOOL SMARTTOUCH® SF Catheter, OMNYPULSE™ Platform, and Laminar LAAX System
• Device Type: Ablation Systems, Catheters, and LAA Closure Devices
• Ablation Energy Source: Pulse Field and Radiofrequency
• Integrated Technologies: Contact Force Sensing

Recent Developments

In April 2026, Johnson & Johnson announced the European launch of VARIPULSE Pro following CE Mark approval. The next-generation platform introduced a revised pulse sequence designed to improve procedural efficiency and was integrated with the CARTO 3 System for cardiac mapping and lesion-delivery guidance. The company stated that the new sequence enables ablation five times faster than the previous sequence while generating equivalent lesions.

To know more about the recent initiatives of Johnson & Johnson and other atrial fibrillation companies, access full report.

5. Medtronic

Company Overview

Medtronic is a global healthcare technology company with a broad portfolio spanning cardiac rhythm management and catheter-based ablation. Within atrial fibrillation, the company's PFA portfolio includes the PulseSelect PFA System and the Affera family of mapping and ablation technologies. These platforms provide physicians with different procedural approaches, ranging from single-shot pulmonary vein isolation to focal, mapping-integrated ablation for more complex AFib cases.
The Affera Mapping and Ablation System with Sphere-9 Catheter combines high-density cardiac mapping with dual-energy pulsed field and radiofrequency ablation. The system is designed to reduce catheter exchanges and allow electrophysiologists to select the preferred energy modality during an individual procedure. Medtronic has further expanded this portfolio through the Sphere-360 catheter, designed as an all-in-one mapping and single-shot PFA catheter for paroxysmal atrial fibrillation.

List of Atrial Fibrillation Devices Offered Based on Product Name, Device Type, Ablation Energy Source, and Integrated Technologies

The section provides information on various atrial fibrillation solutions being offered by Medtronic, along with details on the product name, device type, ablation energy source, and integrated technologies.

• Product Name: PulseSelect, Arctic™ Front Advance, Arctic Front Advance Pro™ Cardiac Cryoablation, Arctic Front Advance Pro™ Cryoballoon, Freezor™ Cardiac Cryoablation Catheter, Freezor™ XTRA Cardiac Cryoablation Catheter, Freezor™ MAX Cardiac Cryoablation Catheter, Affera™ Mapping and Ablation System, Sphere-9™, DiamondTemp™ ablation catheter
• Device Type: Ablation Systems and Catheters
• Ablation Energy Source: Pulse Field, Radiofrequency, and Cryoablation
• Integrated Technologies: Ballon-based and Others

Recent Developments

In January 2026, Medtronic received CE Mark for the Sphere-360 PFA catheter for paroxysmal atrial fibrillation and announced the first patient procedures in its Horizon 360 US IDE pivotal study. The Sphere-360 system combines mapping and single-shot PFA within one catheter and integrates with the Affera platform. Medtronic also reported that PulseSelect was available in more than 35 countries, while Affera with Sphere-9 had received approvals across several major markets.

To know more about the recent initiatives of Medtronic and other atrial fibrillation companies, access full report.

What About Other Atrial Fibrillation Companies Around the World?

The above article features the top five atrial fibrillation companies selected from a pool of around 120 companies that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

1. https://ir.atricure.com/news-releases/news-release-details/atricure-announces-first-patients-treated-novel-dual-energy
2. https://news.bostonscientific.com/2026-04-26-Data-at-Heart-Rhythm-2026-highlight-key-Boston-Scientific-therapies
3. https://www.jnj.com/media-center/press-releases/johnson-johnson-advances-pulsed-field-ablation-portfolio-with-the-launch-of-varipulse-pro-in-europe
4. https://news.medtronic.com/2026-01-23-Affera-TM-momentum-continues-as-Medtronic-announces-CE-Mark-in-Europe-and-U-S-IDE-first-cases-for-Sphere-360-TM-PFA-catheter-to-treat-paroxysmal-atrial-fibrillation